Q-omics provides the consensus-scored TCEAL5 profile across patient tissues and cancer cell-line models. TCEAL5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TCEAL5 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TCEAL5 protein abundance shows 14,674 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight BLCA, KIRC, and UCEC as cancer lineages where TCEAL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEAL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEAL5 survival associations across molecular data types. TCEAL5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEAL5 RNA expression–survival associations across cancer types. High TCEAL5 expression shows unfavorable associations in BLCA, COAD, STAD and UVM, but favorable associations in BRCA and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for TCEAL5 RNA expression.
This table summarizes TCEAL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TCEAL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEAL5 shows lower tumor expression in KIRC, COAD, KICH, THCA, HNSC and STAD. The KIRC box plot shows higher TCEAL5 RNA expression in normal versus tumor tissue (log2 FC = −0.591, t-test p < 0.001).
This table shows molecular features associated with TCEAL5 in patient tissues and cancer cell lines. In patient samples, TCEAL5 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEAL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
